EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Paul K Paik iD, Ravi K Goyal iD, Beilei Cai iD, Mark A Price, Keith L Davis iD, Valerie Derrien Ansquer iD, Nydia Caro, Teddy R Saliba

Future Oncology · 01.01.2023 · 19 (3) · 217-228

DOI: 10.2217/fon-2022-1133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, online erschienen am 07.02.2023. Verfasst von Paul K Paik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Manhattan, NY 10065, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Materials & methods: Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-world overall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed.

Results

68 eligible patients were analyzed. In patients treated with first-line (1L) capmatinib (n = 55), the rwORR was 90.9% systemically and 87.3% intracranially; median systemic rwPFS was 14.1 months. Among radiation-naive patients on 1L capmatinib (n = 20), rwORR was 85.0%, both systemically and intracranially; median systemic rwPFS was 14.1 months.

Conclusion

This study showed substantial systemic and intracranial effectiveness for capmatinib in real-world setting; findings were consistent for RT-naive patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansErbB ReceptorsExonsMutationRetrospective StudiesBenzamidesImidazolesTriazinesProto-Oncogene Proteins c-met

Stichwörter der Autor:innen

brain metastasescapmatinibmedical chart reviewnon-small-cell lung cancertreatment patterns

Substanzen

ErbB ReceptorscapmatinibBenzamidesImidazolesTriazinesMET protein, humanProto-Oncogene Proteins c-met

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Manhattan, NY 10065, USA.
  • Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
  • RTI Health Solutions, 3040 E Cornwallis Road, Research Triangle Park, NC 27709, USA.
  • Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ 07936, USA.

ORCID-Profile: Paul K Paik, Ravi K Goyal, Beilei Cai, Keith L Davis, Valerie Derrien Ansquer

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Paik, P. K., Goyal, R. K., Cai, B., Price, M. A., Davis, K. L., Ansquer, V. D., Caro, N., & Saliba, T. R. (2023). Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncology, 19(3), 217-228. https://doi.org/10.2217/fon-2022-1133

Vancouver

Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Ansquer VD, et al. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncology. 2023;19(3):217-228. doi:10.2217/fon-2022-1133

BibTeX
@article{Paik2023,
  author = {Paik, Paul K and Goyal, Ravi K and Cai, Beilei and Price, Mark A and Davis, Keith L and Ansquer, Valerie Derrien and Caro, Nydia and Saliba, Teddy R},
  title = {Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib},
  journal = {Future Oncology},
  year = {2023},
  volume = {19},
  number = {3},
  pages = {217--228},
  doi = {10.2217/fon-2022-1133}
}
Kostenlos starten →